INTUNIV (Guanfacine) Extended Release Tablets For ADHD In Children And Adolescents Approved By FDA
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, has announced that it has received approval from the US Food and Drug Administration (FDA) for INTUNIV™ (guanfacine) Extended Release Tablets for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years. (Source: Health News from Medical News Today)
National evaluation of the Department of Health's integrated care pilots
This report is the final output of an evaluation of the 16 Department of Health Integrated Care Pilots. The report covers the main findings, efforts and inputs, and facilitators and barriers to success of each pilot, and provides an account of the evaluation activities conducted, the data collected and the analyses completed.
Report
Department of Health - publications (Source: The Kings Fund - Health Management Specialist Collection)
